中西医结合治疗小儿支原体肺炎多中心疗效评价研究(1)
摘要 目的：通過开展中西医结合综合治疗方案治疗小儿支原体肺炎的临床疗效评价研究，评价中医药在小儿支原体肺炎治疗中的有效性和安全性。方法：本临床试验为多中心、前瞻性队列研究，按照治疗方案的不同，自然形成单纯西医治疗组(西医组)和中西医结合治疗组(中西医组)。西医组采用阿奇霉素基础治疗，中西医组在基础治疗的同时，结合中医内服外治方案。结果：临床疗效西医组的痊愈率为18.9%，显效率为78.9%，有效率为100%(n=90)，中西医组痊愈率31.9%，显效率76.8%，有效率为100%(n=310)；2组痊愈率比较，差异有统计学意义(P<0.05)；2组显效率和有效率比较差异无统计学意义(P>0.05)。结论：中西医组疗效明显优于西医组。
关键词 支原体肺炎；小儿；中西医结合；疗效评价
MultiCenter Efficacy Evaluation Study of Treating Pediatric Mycoplasma Pneumonia with Chinese Medicine Integrated with Western Medicine
Jiang Zhiyan， Wang Xuefeng， Wang Lining， Qin Yanhong， Xu Hua， Bai Xiaohong， Jiang Yonghong， Xiao Zhen， Lin Yan
(Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine， Shanghai 200032，China)
Abstract Objective：To evaluate the efficacy of combined treatment to mycoplasma pediatric pneumonia and the effectiveness and safety of TCM. Methods：The clinical experiment is a multicentered， prospective cohort study. According to different treatments， western medicine group and TCM integrated with western medicine group were naturally set up. Western medicine treatment group were given azithromycin. While on this basis， integrated group was treated by TCM internal and external medication. Results：The cure rate of western medicine group was 18.9%， significant efficiency was 78.9%， and the effective rate 100% (n=90). The cure rate of the integrated group was 31.9%， significant efficiency rate 76.8%， and the effective rate 100% (n=310). Cure rate between the two groups has statistically significant difference (P<0.05). However， no significant difference exist in regards to significant efficacy rate and effective rate between the two groups (P>0.05). Conclusion：Intergrated Chinese Medicine with Western Medicine has higher efficacy rate.
Key Words Mycoplasma pneumonia； Pediatric； Chinese Medicine Integrated with Western Medicine； Efficacy evaluation
中图分类号：R272.5；R254.9；R242文献标识码：Adoi：10.3969/j.issn.1673-7202.2017.03.014
目前肺炎支原体(Mycoplasma Pneumoniae，MP)感染已成为导致社区获得性肺炎(Community Acquired Pneumonia，CAP)最重要的病原体之一，国外研究中发现，小儿支原体肺炎(Mycoplasma Pneumoniae Pneumonia，MPP)在社区获得性肺炎中占20%～40%[1]。近年来重症及难治性支原体肺炎的报导日益增多，且患儿病情易发展迅速，易出现多脏器的肺外并发症。大环内酯类抗生素在儿童呼吸道疾病中的大量应用，又导致了抗生素广泛的耐药性。因此制定科学合理的MPP治疗方案，以减少发生重症及难治性MPP，为目前最为重要的对策。因儿童临床药物试验的局限性，缺少大病例前瞻性临床随机对照研究，也尚无统一规范的MPP诊疗方案。本课题组自2004年“十五”攻关项目起，开展对小儿肺炎的大量临床病例研究及基础实验研究。研究发现，MP感染致肺炎发生率逐年上升，因此，一套完整有效的临床诊疗方案急需规范并推广。本课题组开展了一系列针对MPP的基础及临床研究，并形成了一套中西医结合治疗MPP的方案。该治疗方案已在本市各级医院推广应用。
1 资料与方法, http://www.100md.com(姜之炎 王雪峰 王立宁 秦艳红 许华 白晓红 姜永红 肖臻 林燕)
关键词 支原体肺炎；小儿；中西医结合；疗效评价
MultiCenter Efficacy Evaluation Study of Treating Pediatric Mycoplasma Pneumonia with Chinese Medicine Integrated with Western Medicine
Jiang Zhiyan， Wang Xuefeng， Wang Lining， Qin Yanhong， Xu Hua， Bai Xiaohong， Jiang Yonghong， Xiao Zhen， Lin Yan
(Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine， Shanghai 200032，China)
Abstract Objective：To evaluate the efficacy of combined treatment to mycoplasma pediatric pneumonia and the effectiveness and safety of TCM. Methods：The clinical experiment is a multicentered， prospective cohort study. According to different treatments， western medicine group and TCM integrated with western medicine group were naturally set up. Western medicine treatment group were given azithromycin. While on this basis， integrated group was treated by TCM internal and external medication. Results：The cure rate of western medicine group was 18.9%， significant efficiency was 78.9%， and the effective rate 100% (n=90). The cure rate of the integrated group was 31.9%， significant efficiency rate 76.8%， and the effective rate 100% (n=310). Cure rate between the two groups has statistically significant difference (P<0.05). However， no significant difference exist in regards to significant efficacy rate and effective rate between the two groups (P>0.05). Conclusion：Intergrated Chinese Medicine with Western Medicine has higher efficacy rate.
Key Words Mycoplasma pneumonia； Pediatric； Chinese Medicine Integrated with Western Medicine； Efficacy evaluation
中图分类号：R272.5；R254.9；R242文献标识码：Adoi：10.3969/j.issn.1673-7202.2017.03.014
目前肺炎支原体(Mycoplasma Pneumoniae，MP)感染已成为导致社区获得性肺炎(Community Acquired Pneumonia，CAP)最重要的病原体之一，国外研究中发现，小儿支原体肺炎(Mycoplasma Pneumoniae Pneumonia，MPP)在社区获得性肺炎中占20%～40%[1]。近年来重症及难治性支原体肺炎的报导日益增多，且患儿病情易发展迅速，易出现多脏器的肺外并发症。大环内酯类抗生素在儿童呼吸道疾病中的大量应用，又导致了抗生素广泛的耐药性。因此制定科学合理的MPP治疗方案，以减少发生重症及难治性MPP，为目前最为重要的对策。因儿童临床药物试验的局限性，缺少大病例前瞻性临床随机对照研究，也尚无统一规范的MPP诊疗方案。本课题组自2004年“十五”攻关项目起，开展对小儿肺炎的大量临床病例研究及基础实验研究。研究发现，MP感染致肺炎发生率逐年上升，因此，一套完整有效的临床诊疗方案急需规范并推广。本课题组开展了一系列针对MPP的基础及临床研究，并形成了一套中西医结合治疗MPP的方案。该治疗方案已在本市各级医院推广应用。
1 资料与方法, http://www.100md.com(姜之炎 王雪峰 王立宁 秦艳红 许华 白晓红 姜永红 肖臻 林燕)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺炎 > 支原体肺炎